Philipp Lohneis1, Silvia Darb-Esfahani1, Manfred Dietel1, Ioana Braicu2, Jalid Sehouli2, Ruza Arsenic3. 1. Institute of Pathology, Charité, University Hospital Berlin, Berlin, Germany. 2. Department of Gynaecology, Charité, University Hospital Berlin, and Tumorbank Ovarian Cancer, TOC, Berlin, Germany. 3. Institute of Pathology, Charité, University Hospital Berlin, Berlin, Germany ruza.arsenic@charite.de.
Abstract
BACKGROUND/AIM: 3-Phosphoinositide-dependent protein kinase-1 (PDK1) mediates the cellular effects of various growth factors. Increased PDK1 expression is present in various cancers, suggesting that PDK1 may be a critical oncogene in cancer progression. However, only limited data exist on PDK1 expression in ovarian serous cancer. MATERIALS AND METHODS: We used tissue microarrays to analyze PDK1 expression in 253 primary ovarian serous carcinoma samples. RESULTS: A statistically significant negative correlation between PDK1 expression and tumor grade was found. In the high-grade group of ovarian serous carcinomas (n=189), there was a statistically significant difference in overall survival between cases with positive and negative PDK1 expression (p=0.035); positive cases showed longer overall survival. Multivariate analysis confirmed that slight PDK1 expression was an independent indicator for prolonged overall survival (HR=0.51, 95% CI=0.28-0.92, p=0.025). CONCLUSION: PDK1 appears to be a prognostic marker and a possible therapeutic target in ovarian serous carcinoma. Copyright
BACKGROUND/AIM: 3-Phosphoinositide-dependent protein kinase-1 (PDK1) mediates the cellular effects of various growth factors. Increased PDK1 expression is present in various cancers, suggesting that PDK1 may be a critical oncogene in cancer progression. However, only limited data exist on PDK1 expression in ovarian serous cancer. MATERIALS AND METHODS: We used tissue microarrays to analyze PDK1 expression in 253 primary ovarian serous carcinoma samples. RESULTS: A statistically significant negative correlation between PDK1 expression and tumor grade was found. In the high-grade group of ovarian serous carcinomas (n=189), there was a statistically significant difference in overall survival between cases with positive and negative PDK1 expression (p=0.035); positive cases showed longer overall survival. Multivariate analysis confirmed that slight PDK1 expression was an independent indicator for prolonged overall survival (HR=0.51, 95% CI=0.28-0.92, p=0.025). CONCLUSION:PDK1 appears to be a prognostic marker and a possible therapeutic target in ovarian serous carcinoma. Copyright
Authors: Tereza Golias; Ioanna Papandreou; Ramon Sun; Bhavna Kumar; Nicole V Brown; Benjamin J Swanson; Reetesh Pai; Diego Jaitin; Quynh-Thu Le; Theodoros N Teknos; Nicholas C Denko Journal: Sci Rep Date: 2016-08-08 Impact factor: 4.379